Auriga Laboratories gets marketing license for Aquoral dry mouth spray

By Angela McDaniels

Seattle, Sept. 18 - Auriga Laboratories, Inc. said it acquired the exclusive license to market Aquoral, a patented prescription mouth spray device approved by the Food and Drug Administration for the treatment of xerostomia, from Montesson, France-based therapeutics developer Laboratoires Carilene.

The terms of the deal include three payments totaling $1.5 million and a supply agreement with a 5% royalty return, according to a company news release.

Xerostomia, characterized by dry mouth, can be caused by autoimmune diseases and as a side-effect of more than 400 prescription medications. Auriga said the current size of the prescription marketplace for xerostomia medications is about $54 million.

Auriga Laboratories is a specialty pharmaceutical company based in Norcross, Ga., that develops and markets new prescription products for approved drugs using proprietary drug delivery technologies and reformulation strategies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.